WELTERBI-250 is a Terbinafine 250 mg oral antifungal tablet designed for the systemic management of appropriate dermatological and superficial fungal infections. It offers a well-established mechanism directed against fungal ergosterol biosynthesis and is particularly relevant to dermatophyte-focused treatment strategies. As a professional PCD Pharma Derma product, WELTERBI-250 provides physicians with a practical systemic antifungal option for selected skin and nail infections where oral therapy is considered clinically appropriate.
It is an oral antifungal used for susceptible dermatophyte infections, including selected nail and skin infections.
Systemic therapy can reach the nail through the bloodstream and may be more appropriate when infection is extensive or involves the nail unit.
No. The causative organism and infection site should be appropriately assessed because terbinafine is particularly effective against dermatophytes.
Before starting oral terbinafine, healthcare professionals should review the indication carefully and consider liver history and relevant concomitant medicines. Prolonged treatment, especially for nail disease, should follow appropriate clinical assessment. Patients should be advised to complete the prescribed course and avoid self-discontinuation simply because symptoms improve early. New liver-related symptoms or severe skin reactions require prompt medical evaluation. Drug interactions should also be reviewed when multiple medicines are being taken.
Terbinafine tablets may cause gastrointestinal complaints such as nausea, abdominal discomfort, diarrhoea or indigestion. Headache and taste disturbance can also occur. Less commonly, patients may develop skin reactions, itching or other hypersensitivity effects. Oral terbinafine has clinically important hepatic considerations, and significant liver injury is uncommon but potentially serious. Patients should report persistent nausea, loss of appetite, dark urine, pale stools, unusual tiredness or yellowing of the skin or eyes promptly. Taste or smell disturbances may occasionally persist after treatment.
WELTERBI-250 contains Terbinafine, an allylamine antifungal agent that interferes with fungal cell-membrane formation by inhibiting the enzyme squalene epoxidase. This causes depletion of ergosterol, an essential component of the fungal cell membrane, while allowing accumulation of toxic intracellular squalene. The resulting membrane dysfunction leads to inhibition of fungal growth and, at therapeutic concentrations against susceptible organisms, fungal cell death. This mechanism makes terbinafine particularly relevant in dermatophyte infections involving skin, nails and related keratinised tissues.
